Fred H. Mermelstein
Fundador en Pear Tree Pharmaceuticals, Inc. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Julia Novina | F | - |
SanaRx Biotherapeutics, Inc.
SanaRx Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology SanaRx Biotherapeutics, Inc. is a biotechnology company. It serves patients with orphan diseases of the alimentary tract. The company is headquartered in Medford, MA.
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 años |
Daniel B. Carr | M | 76 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 20 años |
Carl Novina | M | - |
SanaRx Biotherapeutics, Inc.
SanaRx Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology SanaRx Biotherapeutics, Inc. is a biotechnology company. It serves patients with orphan diseases of the alimentary tract. The company is headquartered in Medford, MA.
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 años |
Janet Chollet | M | - |
Pear Tree Pharmaceuticals, Inc.
Pear Tree Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pear Tree Pharmaceuticals, Inc. operates as a development stage company with interests in developing prescription products for women. It offers products that treat and prevent diseases, symptoms, and conditions associated with menopause and cancer chemotherapy. The company was founded by Stephen Charles Rocamboli, Fred H. Mermelstein, Janet Chollet and Martin J. Driscoll in July 2007 and is headquartered in Auburndale, MA. | 17 años |
Rostislav Raykov | M | 48 | 15 años | |
John K. Whisnant | M | - |
Pear Tree Pharmaceuticals, Inc.
Pear Tree Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pear Tree Pharmaceuticals, Inc. operates as a development stage company with interests in developing prescription products for women. It offers products that treat and prevent diseases, symptoms, and conditions associated with menopause and cancer chemotherapy. The company was founded by Stephen Charles Rocamboli, Fred H. Mermelstein, Janet Chollet and Martin J. Driscoll in July 2007 and is headquartered in Auburndale, MA. | 17 años |
Dominique Verhelle | M | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 años |
Kenneth Anderson | M | 72 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 años |
Drew Dennison | M | - |
SanaRx Biotherapeutics, Inc.
SanaRx Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology SanaRx Biotherapeutics, Inc. is a biotechnology company. It serves patients with orphan diseases of the alimentary tract. The company is headquartered in Medford, MA. | - |
Barry A. Polisky | M | 78 |
SanaRx Biotherapeutics, Inc.
SanaRx Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology SanaRx Biotherapeutics, Inc. is a biotechnology company. It serves patients with orphan diseases of the alimentary tract. The company is headquartered in Medford, MA.
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
John C. Wang | M | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Anne Alexis Coté Taylor | F | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Martha D. Turner | F | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Kurt H. Stenzel | M | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Henry S. Steffens | M | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Barry H. Smith | M | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Seymour H. Wigod | M | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Sidney R. Knafel | M | 93 |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Jeanine Bortel | F | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Lori Friedman | M | 60 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 1 años |
Stuart D. Saal | M | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Susan Langer | F | 33 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 años |
Christine Henderson | F | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
Cathy Folster | F | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 años |
Salvatore DeSena | M | - |
NX Development Corp.
NX Development Corp. Medical SpecialtiesHealth Technology NX Development Corp. operates as a life science company. It develops Gleolan oral solutions which helps in identifying malignant glioma, a type of brain tumor in adult patients. It allows surgeons to visualize brain tumors during surgery. The company was founded by Alan Ezrin and is headquartered in Lexington, KY. | 2 años |
Tom Erickson | M | - |
SanaRx Biotherapeutics, Inc.
SanaRx Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology SanaRx Biotherapeutics, Inc. is a biotechnology company. It serves patients with orphan diseases of the alimentary tract. The company is headquartered in Medford, MA. | - |
Sandage Bobby | M | - |
SanaRx Biotherapeutics, Inc.
SanaRx Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology SanaRx Biotherapeutics, Inc. is a biotechnology company. It serves patients with orphan diseases of the alimentary tract. The company is headquartered in Medford, MA. | - |
Rosa Sabater | F | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Ingrid Magean Bell | F | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Rosanne Raso | F | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Marc Rubin | M | 69 |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Alain J. Cohen | M | 57 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
Robert S. Saunders | M | - |
NX Development Corp.
NX Development Corp. Medical SpecialtiesHealth Technology NX Development Corp. operates as a life science company. It develops Gleolan oral solutions which helps in identifying malignant glioma, a type of brain tumor in adult patients. It allows surgeons to visualize brain tumors during surgery. The company was founded by Alan Ezrin and is headquartered in Lexington, KY. | - |
Richard D. Hall | M | 67 |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Arthur Becker | M | 74 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 años |
William McKee | M | 62 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
Elena Prokupets | M | 69 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
Charlotte M. Ford | F | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Stephen S. Mills | M | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Drew Dennison | M | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 años |
Bruce R. Gordon | M | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Ulrich Kosciessa | M | - |
NX Development Corp.
NX Development Corp. Medical SpecialtiesHealth Technology NX Development Corp. operates as a life science company. It develops Gleolan oral solutions which helps in identifying malignant glioma, a type of brain tumor in adult patients. It allows surgeons to visualize brain tumors during surgery. The company was founded by Alan Ezrin and is headquartered in Lexington, KY. | - |
Josh Abramowitz | M | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Charles Rizzo | M | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Malcolm Salter | M | 84 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 años |
Andrea Armstrong | F | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 años |
Murdock Gregory | M | - |
NX Development Corp.
NX Development Corp. Medical SpecialtiesHealth Technology NX Development Corp. operates as a life science company. It develops Gleolan oral solutions which helps in identifying malignant glioma, a type of brain tumor in adult patients. It allows surgeons to visualize brain tumors during surgery. The company was founded by Alan Ezrin and is headquartered in Lexington, KY. | - |
Bobby Sandage | M | 70 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
Robert Fried | M | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | - |
Todd Kaloudis | M | - |
SanaRx Biotherapeutics, Inc.
SanaRx Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology SanaRx Biotherapeutics, Inc. is a biotechnology company. It serves patients with orphan diseases of the alimentary tract. The company is headquartered in Medford, MA. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Martin Driscoll | M | 65 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA.
Pear Tree Pharmaceuticals, Inc.
Pear Tree Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pear Tree Pharmaceuticals, Inc. operates as a development stage company with interests in developing prescription products for women. It offers products that treat and prevent diseases, symptoms, and conditions associated with menopause and cancer chemotherapy. The company was founded by Stephen Charles Rocamboli, Fred H. Mermelstein, Janet Chollet and Martin J. Driscoll in July 2007 and is headquartered in Auburndale, MA. | 2 años |
Douglas A. Hamilton | M | 57 |
PolaRx Biopharmaceuticals
PolaRx Biopharmaceuticals Miscellaneous Commercial ServicesCommercial Services Part of Swedish Orphan Biovitrum AB, PolaRx Biopharmaceuticals is a company that manufactures TriOxide drugs for the treatment of leukemia and other cancers. The company is based in New York, NY. The company was founded by Fred H. Mermelstein, Peter Morgan Kash, Raymond P. Warrell. PolaRx Biopharmaceuticals was acquired by CTI BioPharma Corp., part of Swedish Orphan Biovitrum AB from June 27, 2023 on January 13, 2000 for $17.50 million.
Paramount Capital Investments LLC
Innovative Drug Delivery Systems, Inc.
Innovative Drug Delivery Systems, Inc. Pharmaceuticals: MajorHealth Technology IDDS is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. IDDS’s product candidates address the market segment for prescription medications focused on treating acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post operative pain, orthopedic injury, procedural pain, burn pain and trauma. The product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments.
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 5 años |
Stephen Rocamboli | M | 52 |
Pear Tree Pharmaceuticals, Inc.
Pear Tree Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pear Tree Pharmaceuticals, Inc. operates as a development stage company with interests in developing prescription products for women. It offers products that treat and prevent diseases, symptoms, and conditions associated with menopause and cancer chemotherapy. The company was founded by Stephen Charles Rocamboli, Fred H. Mermelstein, Janet Chollet and Martin J. Driscoll in July 2007 and is headquartered in Auburndale, MA. | 10 años |
William P. Peters | M | 72 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 7 años |
Robert W. Butts | M | 50 | - | |
Robert Andrade | M | 49 | 4 años | |
Claudio F. Bussandri | M | 76 | 4 años | |
William G. Breen | M | 78 | 4 años | |
Arthur T. Porter | M | 68 | 7 años | |
Douglas G. Watson | M | 79 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA.
Innovative Drug Delivery Systems, Inc.
Innovative Drug Delivery Systems, Inc. Pharmaceuticals: MajorHealth Technology IDDS is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. IDDS’s product candidates address the market segment for prescription medications focused on treating acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post operative pain, orthopedic injury, procedural pain, burn pain and trauma. The product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments. | 9 años |
Leonard M. C. Firestone | M | - |
Innovative Drug Delivery Systems, Inc.
Innovative Drug Delivery Systems, Inc. Pharmaceuticals: MajorHealth Technology IDDS is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. IDDS’s product candidates address the market segment for prescription medications focused on treating acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post operative pain, orthopedic injury, procedural pain, burn pain and trauma. The product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments. | 2 años |
Stephen Tulipano | M | 65 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 4 años |
Peter Karmanos | M | 81 | - | |
Curtis Wright | M | - |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | - |
Thomas Spector | M | 80 | 4 años | |
Eric Lang | M | - |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | - |
Susan J. Schniepp | F | - |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | - |
Peter D. Kiernan | M | 70 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 4 años |
James A. Klein | M | 61 | 5 años | |
Brian E. Huber | M | - | - | |
Michael Moshman | M | - |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | - |
Rajesh K. Malik | M | 65 | 3 años | |
Georg Nebgen | M | 62 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 4 años |
Peter Morgan Kash | M | 62 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | - |
Donald William Kufe | M | 79 | 6 años | |
Peter Morand | M | 88 | 11 años | |
Jackie Marie Clegg | F | 62 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 6 años |
David B. Bernstein | M | 61 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | - |
Frederick Pierce | M | 63 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | - |
Neil William Flanzraich | M | 80 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 4 años |
Michael G. Martin | M | 72 | 3 años | |
John Taylor | M | 54 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | 1 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 82 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Fred H. Mermelstein
- Red Personal